Form 8-K - Current report:
SEC Accession No. 0001683168-24-008765
Filing Date
2024-12-17
Accepted
2024-12-16 19:00:07
Documents
15
Period of Report
2024-12-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT coeptis_8k.htm   iXBRL 8-K 32040
2 PRESS RELEASE coeptis_ex9901.htm EX-99.1 15983
  Complete submission text file 0001683168-24-008765.txt   272113

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE coep-20241212.xsd EX-101.SCH 3263
4 XBRL DEFINITION FILE coep-20241212_def.xml EX-101.DEF 26557
5 XBRL LABEL FILE coep-20241212_lab.xml EX-101.LAB 36481
6 XBRL PRESENTATION FILE coep-20241212_pre.xml EX-101.PRE 25181
17 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5580
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 241553215
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)